Abstract
Background Schizandrin A is major components extracted from Schisandra chinenzis-Turcz. Baill and Schisandra sphenanthear Rend. etWils. Schizandrin A exhibits remarkable hepatoprotective, antiviral and anti-inflammatory effects. However, the anti-tumor effects and its molecular mechanism were still known limited.
Methods The affinity between Schizandrin A and COX-2/ALOX5 protein was analyzed using network pharmacology, computer molecular docking, and surface plasmon resonance experiments. Bioinformatic analysis and review of clinical characteristics were conducted to assess the necessity of simultaneous blocking of COX-2 and ALOX5 in pancreatic cancer (PC). LC/MS metabolomics and RNA-sequencing were utilized to investigate the effects of schizandrin A on the activation and expression of COX-2/ALOX5 in PC cells. Biological function experiments were conducted to investigate the inhibitory effects of Schizandrin A on PC cell proliferation and cancer-associated fibroblast activation in vitro and in vivo.
Results Schizandrin A demonstrated a high affinity for binding directly with COX-2 and ALOX5, with kinetic association constants of 14.8 μM and 21.8 μM, respectively. PC exhibited a significant COX-2/ALOX5 signature, while PC cases with a high COX-2/ALOX5 signature showed lower overall survival and disease-free survival rates. Treatment of PC cells with schizandrin A resulted in decreased COX-2/ALOX5 activity and expression, leading to inhibition of leukotriene and prostaglandin production, as well as suppression of the downstream pathway NF-kappaB signaling. Schizandrin A demonstrated significant inhibitory effects on the proliferation and sphericity of PC cells in vitro, as well as on cell proliferation in vivo, while exhibiting low toxicity to normal tissues. Treatment of conditioned medium from PC cells with schizandrin A resulted in reduced induction of normal fibroblasts into cancer-associated fibroblasts. Furthermore, mutations in the binding sites of ALXO5 (Arg246) and COX-2 proteins (Ile124 and Ser126) resulted in a significant decrease in affinity to Schizandrin A, and blocking the inhibitory effects of schizandrin A.
Conclusions Taken together, schizandrin A directly bound with COX-2 and ALOX5, reduced their activation and leukotrienes and prostaglandins production, thus exhibiting distinguished effects on suppressing PC proliferation and inhibiting the ability of PC cell to induce normal fibroblasts to transform into tumor-associated fibroblasts. Therefore, schizandrin A represents a potentially novel therapeutic approach for PC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Natural Science Foundation of China (No. U1812403), National Natural Science Foundation of China (No.82103681), Education Department of Guizhou Province Project (No. YJSCXJH [2020] 147); Cultivation Fund Project for Application of NSFC of Affiliated Hospital of Guizhou Medical University (gyfynsfc-2021-4); Guizhou Provincial High-level Overseas Talents Innovation and Entrepreneurship Selection Funding Project (2018)05]; The Science and Technology Foundationof Health Commission of Guizhou Province (gzwki2022-231).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The collection and utilization of PC specimens were approved by the Human Research Ethics Review Committee at Guizhou Medical University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
